Moleculin Biotech (MBRX) stock took a beating on Wednesday after the clinical-stage pharmaceutical company released results from a Phase 1B/2 study of Annamycin. This study evaluated the safety and effectiveness of Annamycin as a treatment for soft tissue sarcoma lung metastases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Moleculin Biotech Chairman and CEO Walter Klemp said, “Looking ahead, we believe these results strongly support further evaluations of Annamycin for the treatment of STS lung mets and we look forward to exploring opportunities to potentially bring this important treatment option to patients.”
While the clinical trial data was positive, it doesn’t appear to be as strong as investors hoped. As a result, shares of MBRX stock were down 10.71% as of Wednesday morning. That extends its 55.88% year-to-date drop and 82.82% 12-month decline.
Is Moleculin Biotech Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Moleculin Biotech is Strong Buy, based on three Buy ratings over the past three months. With that comes an average MBRX stock price target of $10.67, representing a potential 1,268.65% upside for the shares.
See more MBRX stock analyst ratings
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue